Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Feature|Articles|September 29, 2026
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
Author(s)Nicholas Jacobus
While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
Advertisement
Advertisement
Since July, peptide therapeutics have been caught between two FDA processes moving at very different speeds: an advisory vote toward a narrow, legal path for compounded access, and an enforcement campaign against the sellers who didn't wait for it.
Related to this article
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim CEO — explained.
Advertisement
Advertisement